5th Asian PAD Workshop

doi:10.3400/avd.pad.14.01000

Cited by 3 publications

(1 citation statement)

References 8 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since 1992, the National Health Insurance Program (NHIP) in Japan has approved LA therapy (ten treatments over 3 months) for nonsurgical candidate patients with peripheral arterial disease (Fontaine classification>II) who have an LDL-C above 3.6 mmol/L. 24 Also since 1992, the NHIP in Japan has approved LA therapy, specifically the Liposorber LA-15 System (12 treatments over a 12-week period), for nephritic syndrome patients with a total cholesterol >6.5 mmol/L who have been resistant to conventional therapy. 25 In 2013, the US Food and Drug Administration (FDA) approved LA therapy for the new-onset focal segmental glomerulosclerosis in pre- or post-renal transplant pediatric patients who have been resistant to standard treatment options and who have a glomerular filtration rate >60 mL/min/1.73 m 2 .…”

Section: Review Of Clinical Utility Recommendations Patient Selectimentioning

confidence: 99%

Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection

Julius¹

2016

MDER

View full text Add to dashboard Cite

This review reports the current situation with respect to therapeutic options (lifestyle and drugs) reducing the concentrations of atherogenic low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]). Three lipoprotein apheresis (LA) principles have been realized: precipitation, filtration, and adsorption. Available LA methods are herein described in detail – major components, pumps, extracorporeal volume, treated volume, and anticoagulation. General features of all LA methods as well as pleotropic effects are elaborated. Indications for LA therapy are quoted: homozygous familial hypercholesterolemia (HCH), severe HCH, and isolated elevation of Lp(a) and progress of atherosclerotic disease. A major focus is on the evidence of the effect of LA on cardiovascular outcome data, and the most important publications are cited in this context. The best studies have been performed in patients with elevated Lp(a) in whom cardiovascular events were reduced by more than 80%. Major adverse effects and contraindications are listed. The impact of an LA therapy on patient quality of life and the requirements they have to fulfill are also highlighted. Finally, the future role of LA in treating high-risk patients with high LDL-C and/or high Lp(a) is discussed. It is probable that the significance of LA for treating patients with elevated LDL-C will decrease (with the exception of homozygous familial HCH) due to the application of PCSK9 inhibitors. The antisense oligonucleotide against apolipoprotein(a) could replace LA in patients with high Lp(a), provided positive outcome data are generated.

show abstract

Section: Review Of Clinical Utility Recommendations Patient Selectimentioning

confidence: 99%

Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection

Julius¹

2016

MDER

View full text Add to dashboard Cite

show abstract

History of lipidology and lipoprotein apheresis

Julius

2017

Atherosclerosis Supplements

View full text Add to dashboard Cite

Lipoprotein apheresis

Moriarty

2015

Current Opinion in Lipidology

View full text Add to dashboard Cite

Recent and future lipid-modifying therapies will most likely reduce the practice of lipoprotein apheresis therapy for familial hypercholesterolemia patients. Future implications for lipoprotein apheresis will involve vascular diseases that are at present lacking clinically effective therapy, whereas acute and chronic reductions of lipids, vascular inflammation, and/or rheology may improve the clinical outcome.

show abstract

5th Asian PAD Workshop

Cited by 3 publications

References 8 publications

Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection

Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection

History of lipidology and lipoprotein apheresis

Lipoprotein apheresis

Contact Info

Product

Resources

About